SGEM Xtra: Here Comes the NINDS Again

Ensaios extraídos do podcast de Dr. Ken Milne

• 1995NINDSAnticoagulation & AntithromboticsIn 624 patients with acute ischemic stroke within 3 hours of onset, intravenous alteplase improved 3-month functional outcome compared with placebo.
• 2022Risk of selection bias assessment in the NINDS rt-PA Stroke StudyAnticoagulation & AntithromboticsIn 624 patients randomised in the NINDS rt-PA Stroke Study, covariate-adjusted reanalysis of alteplase versus placebo reduced the reported treatment effects.
• 2004Reanalysis of the NINDS t-PA for Acute Ischemic Stroke Treatment TrialAnticoagulation & AntithromboticsIn 622 patients with acute ischemic stroke, intravenous t-PA within 3 hours of onset increased favorable outcome at 3 months compared with placebo.
• 2005Impact of Imbalances in Baseline Stroke Severity on Outcome in the NINDS rt-PA Stroke StudyAnticoagulation & AntithromboticsIn 624 patients with acute ischemic stroke, intravenous tPA still favoured favourable 3-month outcome over placebo in every severity and time subgroup.
• 2009A Graphic Reanalysis of the NINDS TrialAnticoagulation & AntithromboticsIn 624 NINDS-trial patients with acute ischaemic stroke, alteplase showed 90-day neurologic outcomes only marginally better than placebo on graphic reanalysis.
• 2010Graphic Reanalysis of the Two NINDS-tPA Trials Confirms Substantial Treatment BenefitAnticoagulation & AntithromboticsIn 624 patients with acute ischaemic stroke, intravenous tPA produced greater normalized NIHSS improvement at 90 days than placebo.
• 2020ECASS IIIAnticoagulation & AntithromboticsIn 821 patients with acute ischaemic stroke treated 3-4.5 h after onset, alteplase did not improve 90-day disability versus placebo after adjustment.
• 1999ATLANTIS BAnticoagulation & AntithromboticsIn 613 patients with acute ischaemic stroke 3 to 5 hours after symptom onset, alteplase did not increase excellent neurologic recovery at 90 days compared with placebo.